1-3 of 3
John Dixon
Close
Sort by
Journal Articles

Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure

Bei Bei Ding, PhD, John Dixon Gray, PhD, Nan Zhang, Yanliang Zhang, PhD, Xia Cao, MSc, Irina Krapf, MSc, Qingdong Mark Deng, Angel Wei, MD, Jerome B. Zeldis, MD PhD, Robert D. Knight, MD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Wenzhong Guo, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1942.
https://doi.org/10.1182/blood-2019-131892
Published: 2019
Journal Articles

Development of a Genetically-Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure

Bei Bei Ding, PhD, John Dixon Gray, PhD, Irina Krapf, MSc, Yanliang Zhang, PhD, Nan Zhang, Qingdong Mark Deng, Angel Wei, MD, Robert D. Knight, MD, Jerome B. Zeldis, MD PhD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Wenzhong Guo, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4444.
https://doi.org/10.1182/blood-2019-131586
Published: 2019
Journal Articles

Loss of Mll5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation

Michael Heuser, Damian B. Yap, Malina Leung, Teresa Ruiz de Algara, Alaeddin Tafech, Steven McKinney, John Dixon, Rosemary Thresher, Bill Colledge, Mark Carlton, R. Keith Humphries, Samuel A. Aparicio
Journal: Blood
Blood (2009) 113 (7): 1432–1443.
https://doi.org/10.1182/blood-2008-06-162263
Published: 2009
Includes: Supplemental data